AcuCort AB, a company known for its innovative drug delivery systems, is embarking on a pivotal roadshow across Sweden, inviting investors to engage with its leadership team. The meetings, scheduled in Malmö, Gothenburg, and Stockholm from November 17 to 19, 2026, will provide a platform for CEO Jonas Jönmark and Strategic Alliance Manager Carl Frisk to present AcuCort's strategic direction and discuss the upcoming rights issue.

The rights issue, which runs from November 12 to 26, 2026, aims to raise approximately SEK 70.3 million before issue costs. The funds are earmarked for crucial initiatives, including securing FDA approval for Zeqmelit® and expanding AcuCort's market presence in the US and other regions. Zeqmelit®, a rapidly dissolving oral film of dexamethasone, is already approved in the Nordic countries and marketed with the help of Glenmark Pharmaceuticals in six European markets.

CEO Jonas Jönmark emphasized the significance of this stage in AcuCort's journey, highlighting the company's achievements and future priorities. The roadshow offers a unique opportunity for potential and current investors to gain insights into AcuCort's strategic plans and how the rights issue will bolster its growth trajectory.

The investor meetings will also include a Q&A session, providing a platform for stakeholders to engage directly with AcuCort's leadership. This interactive component is crucial for building investor confidence and clarifying the company's strategic initiatives.

From a financial perspective, the rights issue represents a critical step for AcuCort in securing the necessary capital to fund its ambitious expansion plans. The potential FDA approval for Zeqmelit® could open significant revenue streams in the US, a lucrative market for pharmaceuticals. Additionally, expanding into new markets aligns with AcuCort's long-term growth strategy, potentially enhancing shareholder value.

For investors, the decision to participate in the rights issue should consider AcuCort's strategic positioning, the potential for FDA approval, and the broader market dynamics. Given the promising outlook and strategic initiatives, investors might consider a 'hold' position, assessing the outcomes of the FDA submission and market expansion efforts.